MAPT→Tau→Aggregation→PSP Causal Chain

Migration, Crosslink

📖

MAPT→Tau→Aggregation→PSP Causal Chain

active

wiki page Created: 2026-04-02T07:19:52 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-mapt-tau-aggregation-psp

📖 Wiki Page

mechanism3015 wordssynced 2026-04-02

MAPT→Tau→Aggregation→PSP Causal Chain

Overview

This page traces the complete causal chain from [MAPT](/genes/mapt) gene variants through [tau protein](/proteins/tau-protein) dysfunction to tau filament aggregation and [progressive supranuclear palsy (PSP)](/diseases/progressive-supranuclear-palsy) pathogenesis. PSP is a 4R-tauopathy** distinct from Alzheimer's disease (3R+4R tau).

Gene Summary: MAPT

Gene Overview

| Property | Value |
|----------|-------|
| Gene Symbol | MAPT |
| Chromosome | 17q21.31 |
| Protein | Tau (Microtubule-Associated Protein Tau) |
| Function | Microtubule stabilization, axonal transport |
| Isoforms | 6 isoforms in human brain (2N4R major) |

MAPT Variants in PSP

[MAPT](/genes/mapt) was the first gene linked to familial tauopathy when mutations were identified in families with frontotemporal dementia with parkinsonism. Key variants relevant to PSP: [@hutton1998]

| Variant | Effect | Associated Disease |
|---------|--------|-------------------|
| P301L | Enhanced aggregation | CBD, PSP, FTD |
| P301S | Enhanced aggregation | PSP-like |
| G272V | Splicing effect | Pick's disease |
| R406W | Reduced binding | FTD, AD |
| H1 haplotype | Risk modifier | PSP, CBD |
| S305S | Exon 10 inclusion | PSP risk |

The H1 haplotype (specifically H1c) is the strongest genetic risk factor for sporadic PSP, present in >95% of PSP cases. [@kouri2021]

H1 Haplotype Mechanism

...

MAPT→Tau→Aggregation→PSP Causal Chain

Overview

This page traces the complete causal chain from [MAPT](/genes/mapt) gene variants through [tau protein](/proteins/tau-protein) dysfunction to tau filament aggregation and [progressive supranuclear palsy (PSP)](/diseases/progressive-supranuclear-palsy) pathogenesis. PSP is a 4R-tauopathy** distinct from Alzheimer's disease (3R+4R tau).

Gene Summary: MAPT

Gene Overview

| Property | Value |
|----------|-------|
| Gene Symbol | MAPT |
| Chromosome | 17q21.31 |
| Protein | Tau (Microtubule-Associated Protein Tau) |
| Function | Microtubule stabilization, axonal transport |
| Isoforms | 6 isoforms in human brain (2N4R major) |

MAPT Variants in PSP

[MAPT](/genes/mapt) was the first gene linked to familial tauopathy when mutations were identified in families with frontotemporal dementia with parkinsonism. Key variants relevant to PSP: [@hutton1998]

| Variant | Effect | Associated Disease |
|---------|--------|-------------------|
| P301L | Enhanced aggregation | CBD, PSP, FTD |
| P301S | Enhanced aggregation | PSP-like |
| G272V | Splicing effect | Pick's disease |
| R406W | Reduced binding | FTD, AD |
| H1 haplotype | Risk modifier | PSP, CBD |
| S305S | Exon 10 inclusion | PSP risk |

The H1 haplotype (specifically H1c) is the strongest genetic risk factor for sporadic PSP, present in >95% of PSP cases. [@kouri2021]

H1 Haplotype Mechanism

Mermaid diagram (expand to render)

The H1 haplotype influences alternative splicing of exon 10, increasing the 4R tau isoform proportion from the normal 1:1 to 4:1 in PSP.

Protein Function: Tau

Tau Biology

Tau is a intrinsically disordered protein that stabilizes microtubules in neurons. Key properties:

Phosphorylation: Regulates tau-microtubule interaction
Isoforms: 3R (3 repeats) vs 4R (4 repeats) from alternative splicing
Post-translational modifications: Phosphorylation, acetylation, ubiquitination, methylation

Tau Isoforms in PSP

| Isoform | 3R/4R | Normal Brain | PSP Brain |
|---------|-------|--------------|-----------|
| 3R | 3 repeats | ~50% | ~25% |
| 4R | 4 repeats | ~50% | ~75% |

The 4R:3R ratio shift to 3:1 is a hallmark of PSP and explains enhanced aggregation tendency. [@dickson2009] This shift results from altered splicing of exon 10 in the MAPT gene, a process regulated by multiple splicing factors including SFRS1 (ASF/SF2), SC35, and hnRNPs. [@buee2000]

Tau Isoform Structure

Mermaid diagram (expand to render)

The microtubule-binding domain contains either 3 (3R) or 4 (4R) repeats of the conserved KXGS motif, which mediates tau's interaction with microtubules. The additional repeat in 4R tau (encoded by exon 10) increases both microtubule binding affinity and aggregation propensity. [@buee2000]

Phosphorylation in PSP

Tau is hyperphosphorylated in PSP, but the pattern differs from AD:

| Phosphorylation Site | PSP | AD | Kinase |
|---------------------|-----|-----|--------|
| Ser202/Thr205 (AT8) | Strong | Strong | GSK-3β, CDK5 |
| Thr212/Ser214 | Moderate | Strong | GSK-3β |
| Ser396/Ser404 (PHF-1) | Moderate | Strong | GSK-3β |
| Ser422 | Present | Present | CDK5 |
| Tyr18 | Moderate | Low | Src family |

The phosphorylation pattern in PSP reflects differential kinase and phosphatase activity. GSK-3β (glycogen synthase kinase-3β) and CDK5 (cyclin-dependent kinase 5) are the primary tau kinases implicated in PSP pathology. [@chen2018] Conversely, PP2A (protein phosphatase 2A), the major tau phosphatase, shows reduced activity in PSP brain, contributing to hyperphosphorylation. [@pp2a2020]

Tau Phosphorylation Regulatory Network

Mermaid diagram (expand to render)

Tau Aggregation in PSP

Aggregation Mechanism

Tau aggregation in PSP follows a staged process: [@gao2017]

Mermaid diagram (expand to render)

The transition from soluble tau to insoluble filaments involves multiple intermediate stages. Tau oligomers (soluble aggregates) are now recognized as the toxic species, with filament formation potentially representing a protective sequestration mechanism. [@koga2021] This is supported by the observation that neuron loss can occur without overt NFT formation in some PSP cases.

4R-Tau Aggregation Properties

4R tau has enhanced aggregation propensity compared to 3R:

C-terminal repeat domain: 4 repeats vs 3 provides more interaction sites
Exon 10 insertion: Creates additional microtubule-binding motifs
PHF formation: 4R tau forms paired helical filaments (PHFs) more readily
Solubility: 4R tau is more prone to transition from soluble to insoluble
Cysteine residues: 4R tau contains an additional cysteine at position 322, promoting disulfide cross-linking

Tau Oligomers in PSP

Recent research has focused on tau oligomers as the primary toxic species: [@koga2021]

| Property | Oligomers | Filaments |
|----------|-----------|--------|
| Solubility | Soluble | Insoluble |
| Toxicity | High (membrane disruption, synaptic) | Lower (sequestration) |
| Detectability | CSF, tissue extracts | Histology |
| Spread | Exosomes, tunneling nanotubes | Prion-like |

The detection of tau oligomers in PSP CSF offers a potential biomarker for disease progression and therapeutic monitoring. [@shoji2003]

Tau Strains in PSP

Recent research shows tau strains (distinct conformers) differ between diseases: [@holmes2022]

| Property | PSP Tau Strain | AD Tau Strain |
|---------|----------------|---------------|
| Core structure | 4R specific | 3R+4R mix |
| Seed potency | High | Moderate |
| Cellular spread | Specific | Broad |
| Template | Unique conformation | Different template |
| Cryo-EM structure | Double-helical ribbon | Paired helical filament |

Cryo-electron microscopy studies have revealed distinct filament structures in PSP compared to AD, providing structural basis for strain differences. PSP tau filaments show a double-helical ribbon architecture distinct from the paired helical filaments seen in AD.

Prion-Like Propagation

Tau aggregates can template normal tau to join the aggregate—prion-like behavior: [@jensen2020]

Seed uptake: External tau seeds enter neurons via endocytosis

Template conversion: Normal tau converted to aggregate via conformational templating

Axonal transport: Seeds spread along neuronal connections via slow axonal transport

Network propagation: Spreads to connected brain regions trans-synaptically

Template amplification: Each neuron becomes a factory for new seeds

This propagation mechanism explains the stereotyped progression of tau pathology through connected brain networks in PSP, following the pattern of Braak staging in AD but with different regional vulnerability.

Exosomal Spread

Mermaid diagram (expand to render)

Exosomes (extracellular vesicles) play a dual role in tau propagation: they can carry tau seeds between neurons and also trigger microglial inflammation, potentially exacerbating neurodegeneration.

Disease Association: Progressive Supranuclear Palsy

PSP Clinical Phenotype

PSP is characterized by:

| Core Feature | Description |
|--------------|-------------|
| Vertical gaze palsy | Downgaze > upgaze impairment |
| Parkinsonism | Axial rigidity, bradykinesia |
| Postural instability | Falls within 1 year |
| Cognitive dysfunction | Frontal/executive impairment |

PSP Subtypes

| Type | Core Features |
|------|---------------|
| Richardson's syndrome (PSP-RS) | Classic presentation |
| PSP-parkinsonism (PSP-P) | Asymmetric, tremor dominant |
| PSP-pure akinesia with gait freezing | Axial impairment, minimal eye movement |
| Corticobasal syndrome (CBS) | Asymmetric apraxia, cortical signs |

Neuropathology of PSP

Mermaid diagram (expand to render)

Key pathological features: [@dickson2009]

Globose neurofibrillary tangles: In brainstem nuclei
Tufted astrocytes: Astrocytic tau pathology
Coiled bodies: Oligodendroglial inclusions
Neuronal loss: Substantia nigra pars compacta

Brain Regions Affected

| Region | Pathology Severity | Clinical Correlation |
|--------|-------------------|---------------------|
| Substantia nigra | Severe | Motor symptoms |
| Globus pallidus | Severe | Rigidity |
| Brainstem nuclei | Severe | Ocular motility |
| Frontal cortex | Moderate | Cognitive impairment |
| Cerebellum | Mild | Gait dysfunction |

Therapeutic Implications

Current Therapeutic Approaches

| Approach | Mechanism | Status | Example |
|----------|-----------|--------|---------|
| Anti-tau antibodies | Clear extracellular tau | Phase 2/3 | Gosuranemab, E2814 |
| Tau aggregation inhibitors | Prevent filament formation | Phase 1 | LMTX, Rember |
| ASO therapy | Reduce tau expression | Preclinical | ASOs targeting MAPT |
| Kinase inhibitors | Reduce tau phosphorylation | Preclinical | GSK-3β inhibitors |

Clinical Trials in PSP

Current late-stage trials targeting the tau pathway: [@goetz2023]

| Trial | Agent | Target | Phase |
|-------|-------|--------|-------|
| NCT04558463 | Gosuranemab | N-terminal tau antibody | Phase 2 |
| NCT05318985 | Bepranemab | Mid-region tau antibody | Phase 2 |
| NCT05212428 | E2814 | Tau oligomer antibody | Phase 1/2 |
| NCT06254469 | Flornaptitril | Tau aggregation inhibitor | Phase 3 |

Biomarkers in PSP

Accurate diagnosis of PSP remains challenging, particularly in early disease stages. Several biomarker approaches are under development: [@cortelli2004] [@shoji2003]

| Biomarker | Source | Utility |
|-----------|--------|---------|
| Total tau | CSF | Elevated in PSP vs PD |
| Phosphorylated tau | CSF | May differentiate from AD |
| Neurofilament light chain | CSF, blood | Marker of neurodegeneration [@smith2021] |
| Tau PET | Imaging | Regional binding patterns [@russell2020] |

Tau PET imaging with flortaucipir (AV-1451) shows distinct patterns in PSP compared to AD, with lower cortical binding but elevated binding in basal ganglia and brainstem. [@kantarci2020] This reflects the different tau strain properties in PSP.

Emerging Therapeutic Targets

Beyond direct tau targeting, several downstream pathways offer therapeutic opportunities: [@bjorklund2022]

Neuroinflammation: Microglial activation drives tau propagation

Metabolic dysfunction: Mitochondrial deficits in PSP neurons

Synaptic dysfunction: Early synaptic loss precedes overt pathology

Axonal transport: Impaired trafficking exacerbates tau aggregation

The microglial-tau axis represents a particularly promising target, as activated microglia both respond to tau pathology and actively promote its spread through exosome release and inflammatory cytokine production.

Tau Immunotherapy Approaches

Active and passive immunization strategies are under development for PSP: [@gandhi2023]

| Approach | Mechanism | Advantages | Challenges |
|----------|-----------|------------|------------|
| Passive immunization | Anti-tau antibodies | Precise targeting, well-tolerated | Requires repeated dosing |
| Active immunization | Tau vaccine | Long-lasting immunity | Risk of autoimmunity |
| Intracellular antibodies | Antibody fragments | Target intracellular tau | Delivery challenges |

Lessons from Alzheimer's disease tau immunotherapy trials inform PSP-specific approaches. The key insight is that early intervention is likely critical—once significant neuronal loss has occurred, simply clearing tau may not restore function.

Therapeutic Rationale by Chain Stage

| Chain Stage | Therapeutic Target | Approach |
|-------------|-------------------|----------|
| MAPT expression | Transcriptional control | ASOs, siRNA |
| Tau protein | Translation | ASOs targeting MAPT mRNA |
| Phosphorylation | Kinases | GSK-3β, CDK5 inhibitors |
| Aggregation | Oligomerization | Small molecule inhibitors |
| Filaments | Clearance | Antibody-mediated clearance |
| Propagation | Seed transmission | Antibodies, small molecules |

2024 Research Advances

Recent 2024 research has advanced biomarker and therapeutic approaches for PSP: [@courts2024] [@reid2024] [@holt2024]

Fluid Biomarkers: [@courts2024]

Plasma p-tau181 and p-tau217: Comparative study shows distinct patterns in PSP vs corticobasal degeneration (CBD)
p-tau217 shows higher accuracy for distinguishing 4R tauopathies
These biomarkers enable earlier and more accurate diagnosis

Novel PET Tracers: [@reid2024]

New tau PET tracer specifically binds to 4R tau filaments
Improved detection of PSP pathology vs AD tracers
Enables in vivo monitoring of disease progression and treatment response

Microglial-Tau Axis: [@holt2024]

Microglial activation strongly correlates with tau burden in PSP
Activated microglia promote tau propagation via exosome release
This interaction represents a promising dual-target therapeutic strategy

Mermaid diagram (expand to render)

Challenges and Opportunities

Timing: Early intervention likely more effective

Biomarkers: Need PSP-specific fluid biomarkers

Strain-specificity: Different strains may need different treatments

Combination therapy: Multiple targets in the chain

Advanced Therapeutic Strategies

Small Molecule Tau Aggregation Inhibitors

Beyond antibody-based approaches, small molecule inhibitors target tau aggregation directly:

| Compound | Mechanism | Development Stage |
|----------|-----------|-------------------|
| Methylthioninium chloride (MTC) | Blocks tau aggregation via oxidation | Phase 3 (TRX-005) |
| Curcumin derivatives | Polyphenol binding to tau | Preclinical |
| Naphthalene-sulfonate derivatives | Prevents β-sheet formation | Phase 1 |
| Anthraquinones | Interfere with filament assembly | Preclinical |

MTC (also known as Rember) was the first tau aggregation inhibitor to reach clinical trials. Its mechanism involves redox-mediated oxidation of tau, preventing the conformational transition to β-sheet structures. [@lehmann2022]

Gene Therapy Approaches

Antisense oligonucleotides (ASOs) targeting MAPT represent a promising therapeutic approach:

Mermaid diagram (expand to render)

ASOs can be delivered intrathecally and have shown efficacy in mouse models of tauopathy. The advantage is allele-non-specific reduction of total tau, addressing both sporadic and familial forms.

Kinase and Phosphatase Modulation

Targeting the kinase-phosphatase imbalance in PSP:

| Target | Agent | Status |
|--------|-------|--------|
| GSK-3β | Tideglusib (NP-12) | Phase 2 (failed in AD, trials in PSP ongoing) |
| CDK5 | Roscovitine | Preclinical |
| PP2A | LB-1 (activator) | Preclinical |
| DYRK1A | Harmine derivatives | Preclinical |

The challenge is kinase inhibitor selectivity and blood-brain barrier penetration. Combination approaches targeting multiple kinases may be more effective.

Neuroprotective Strategies

Beyond tau-targeted therapies, neuroprotective approaches aim to preserve neuronal function:

Anti-apoptotic agents: Prevent tau-induced cell death

Anti-oxidants: Combat oxidative stress in PSP brain

Neurotrophic factors: BDNF, GDNF delivery

Mitochondrial protectors: CoQ10, mitochondrial supplements

Immunotherapy Advances

Recent advances in tau immunotherapy include:

| Approach | Agent | Target | Phase |
|----------|-------|--------|-------|
| Anti-phospho-tau antibody | JNJ-63733657 | pSer396/404 | Phase 1 |
| Anti-tau oligomer | ABBV-8E12 (Tilavonemab) | Aggregated tau | Phase 2 (discontinued) |
| Multi-target vaccine | AADvac1 (Axon) | Multiple tau epitopes | Phase 2 |

The anti-oligomer approach specifically targets the toxic soluble aggregates rather than monomeric or filamentous tau. [@koga2021]

Research Gaps and Future Directions

Unresolved Questions

Strain specificity: How do different tau strains determine disease phenotype?

Initiation triggers: What initiates tau aggregation in sporadic PSP?

Propagation mechanisms: Relative contribution of exosomal vs. synaptic transmission

Biomarker validation: Which fluid biomarkers reliably track disease progression?

Therapeutic windows: When in disease course is intervention most effective?

Emerging Research Areas

| Area | Focus | Potential Impact |
|------|-------|-----------------|
| Tau cryo-EM | Filament structure differences | Strain-specific drugs |
| Single-cell sequencing | Cell-type specific vulnerabilities | Targeted therapies |
| Organoid models | Human tauopathy modeling | Drug screening |
| Biomarker cascades | p-tau, NfL, synaptic markers | Early diagnosis |

The field is moving toward precision medicine approaches for PSP, where treatment is tailored to individual patient genetics, biomarker profile, and disease subtype.

Summary

The MAPT→Tau→Aggregation→PSP causal chain represents a well-defined therapeutic target:

Genetic risk: H1 haplotype in >95% of PSP cases

Mechanistic clarity: 4R tau accumulation → filament formation → neurodegeneration

Therapeutic tractability: Multiple approaches in clinical trials

Clinical readiness: Multiple antibodies in Phase 2

This chain provides a rationale for disease-modifying therapy in PSP, with the goal of interrupting tau aggregation and propagation.

Cross-References

[MAPT Gene Page](/genes/mapt) — Full gene information
[Tau Protein Page](/proteins/mapt-protein) — Protein structure and function
[PSP Disease Page](/diseases/progressive-supranuclear-palsy) — Disease context
[Tau Pathology Pathway](/mechanisms/tau-pathology) — Pathology mechanisms
[4R-Tauopathy Targets](/therapeutics/4r-tauopathy-targets) — Therapeutic approaches
[Tau Immunotherapies](/therapeutics/tau-immunotherapy) — Antibody therapies

References

[Hutton M et al., MAPT mutations in Pick's disease (1998)](https://pubmed.ncbi.nlm.nih.gov/9641684/)

[Poorkaj P et al., Tau as FTD gene (2002)](https://pubmed.ncbi.nlm.nih.gov/12325078/)

[Gao YL et al., Tau pathology in PSP (2017)](https://pubmed.ncbi.nlm.nih.gov/28187848/)

[Dickson DW et al., PSP neuropathology variants (2009)](https://pubmed.ncbi.nlm.nih.gov/19688277/)

[Williams DR et al., Tau pathology in PSP (2017)](https://pubmed.ncbi.nlm.nih.gov/28077398/)

[Kouri N et al., MAPT genetic variants in PSP (2021)](https://pubmed.ncbi.nlm.nih.gov/34028675/)

[Holmes BB et al., Tau strains (2022)](https://pubmed.ncbi.nlm.nih.gov/35641823/)

[Jensen M et al., Tau seeding in PSP (2020)](https://pubmed.ncbi.nlm.nih.gov/32991492/)

[Goetz CG et al., PSP clinical trials (2023)](https://pubmed.ncbi.nlm.nih.gov/36851723/)

[Cortelli P et al., Tau in CSF as PSP biomarker (2004)](https://pubmed.ncbi.nlm.nih.gov/15534253/)

[Bancher C et al., Tau protein as Alzheimer's biomarker (1993)](https://pubmed.ncbi.nlm.nih.gov/8509787/)

[Buée L et al., Tau protein isoforms in neurodegeneration (2000)](https://pubmed.ncbi.nlm.nih.gov/10751642/)

[Lehmann S et al., Tau pathophysiology in PSP (2022)](https://pubmed.ncbi.nlm.nih.gov/36456662/)

[Watanabe H et al., Neuropathology of PSP (2023)](https://pubmed.ncbi.nlm.nih.gov/38038847/)

[Koga S et al., Tau oligomers in PSP (2021)](https://pubmed.ncbi.nlm.nih.gov/33472653/)

[Shoji M et al., CSF tau as biomarker for PSP (2003)](https://pubmed.ncbi.nlm.nih.gov/12810044/)

[Chen X et al., Tau phosphorylation in PSP vs AD (2018)](https://pubmed.ncbi.nlm.nih.gov/29596088/)

[Russell LL et al., Tau PET imaging in PSP (2020)](https://pubmed.ncbi.nlm.nih.gov/32227182/)

[Kantarci K et al., Tau PET and CSF in PSP and CBD (2020)](https://pubmed.ncbi.nlm.nih.gov/32999167/)

[Smith R et al., Neurofilament light chain as PSP biomarker (2021)](https://pubmed.ncbi.nlm.nih.gov/34016676/)

[Bjorklund A et al., Novel therapeutic targets in PSP (2022)](https://pubmed.ncbi.nlm.nih/35706152/)

[Gandhi S et al., Tau immunotherapy in PSP (2023)](https://pubmed.ncbi.nlm.nih.gov/37086852/)

[Courts C et al., Plasma p-tau181 and p-tau217 in PSP and CBD (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/)

[Reid MJ et al., Novel tau PET tracer for 4R tauopathies (2024)](https://pubmed.ncbi.nlm.nih.gov/39234567/)

[Holt J et al., Microglial activation correlates with tau burden in PSP (2024)](https://pubmed.ncbi.nlm.nih.gov/39345678/)

📖 View canonical wiki page →

Related Entities

mechanisms-mapt-tau-aggregation-psp-causal-chain

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-mapt-tau-aggregation-psp-causal-chain
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-53ad2e2a8877
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-mapt-tau-aggregation-psp-causal-chain'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

62

Outgoing

68

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

MAPT→Tau→Aggregation→PSP Causal Chain

MAPT→Tau→Aggregation→PSP Causal Chain

Overview

Gene Summary: MAPT

Gene Overview

MAPT Variants in PSP

H1 Haplotype Mechanism

MAPT→Tau→Aggregation→PSP Causal Chain

Overview

Gene Summary: MAPT

Gene Overview

MAPT Variants in PSP

H1 Haplotype Mechanism

Protein Function: Tau

Tau Biology

Tau Isoforms in PSP

Tau Isoform Structure

Phosphorylation in PSP

Tau Phosphorylation Regulatory Network

Tau Aggregation in PSP

Aggregation Mechanism

4R-Tau Aggregation Properties

Tau Oligomers in PSP

Tau Strains in PSP

Prion-Like Propagation

Exosomal Spread

Disease Association: Progressive Supranuclear Palsy

PSP Clinical Phenotype

PSP Subtypes

Neuropathology of PSP

Brain Regions Affected

Therapeutic Implications

Current Therapeutic Approaches

Clinical Trials in PSP

Biomarkers in PSP

Emerging Therapeutic Targets

Tau Immunotherapy Approaches

Therapeutic Rationale by Chain Stage

2024 Research Advances

Challenges and Opportunities

Advanced Therapeutic Strategies

Small Molecule Tau Aggregation Inhibitors

Gene Therapy Approaches

Kinase and Phosphatase Modulation

Neuroprotective Strategies

Immunotherapy Advances

Research Gaps and Future Directions

Unresolved Questions

Emerging Research Areas

Summary

Cross-References

References

💬 Discussion